A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+ metastatic breast cancer (MBC).
Erika Paige Hamilton
No relevant relationships to disclose
Denise A. Yardley
No relevant relationships to disclose
Gabriel N. Hortobagyi
Consultant or Advisory Role - Allergan; Antigen Express; Galena Biopharma; Genentech; Novartis; Pfizer; Sanofi
Research Funding - Novartis
Luke N. Walker
Employment or Leadership Position - Oncothyreon
Stock Ownership - Oncothyreon
Virginia F. Borges
No relevant relationships to disclose
Stacy L. Moulder
Research Funding - Array BioPharma